Docoh
Loading...

RSLS ReShape Lifesciences

Employees

Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


A special meeting of the stockholders of the Obalon Therapeutics, Inc. (the “Company”) was held vritually on May 25, 2021 (the “Special Meeting”) in connection with the Agreement and Plan of Merger (the “Merger Agreement”), dated January 19, 2021, by and among the Company, ReShape Lifesciences, Inc. (“ReShape”), and Optimus Merger Sub, Inc., a wholly owned subsidiary of the Company (“Merger Sub”), pursuant to which, ReShape will merge with and into Merger Sub and survive as a wholly owned subsidiary of the Company (the “Merger”). As a result of the Merger, the Company will be renamed “ReShape Lifesciences Inc.” and ReShape will be renamed ReShape Weightloss Inc.

At the close of business on April 7, 2021, the record date for the Special Meeting, there were 10,021,568 shares of Common Stock outstanding and entitled to vote. Holders of 5,425,656 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), representing 54.1% of the shares entitled to vote, were present at the Special Meeting, either in person vritually or by proxy, constituting a quorum. Set forth below are the voting results from the Special Meeting.

Proposal 1. To approve the issuance of shares of the Common Stock, in connection with the Merger, as described in the Merger Agreement, which required the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively on the proposal.

Votes ForVotes AgainstAbstentions
5,292,226125,9887,442


Proposal 2. To approve the authorization of the board of directors of the Company (the “Board”), in its discretion but in no event later than the date of the 2021 annual meeting of stockholders, to amend the Company’s Restated Certificate of Incorporation, as amended, to effect a reverse stock split of Common Stock, at a ratio in the range of 1-for-3 to 1-for-10 (the “Reverse Stock Split”), such ratio to be determined by the Board and included in a public announcement, as described in the Company’s definitive joint proxy statement/prospectus on Form S-4/A filed with the SEC on April 9, 2021, which required the affirmative vote of the holders of a majority of the voting power of the outstanding shares of Common Stock entitled to vote thereon.

Votes ForVotes AgainstAbstentions
5,112,512286,19126,953


The Company did not call the vote on the adjournment of the Special Meeting as there were sufficient votes to approve Proposal 1 and 2. No other proposals were submitted to a vote of the Company’s stockholders at the Special Meeting.